TICKERNERD
Menu
NAMSNAMSHealthcare · Biotechnology

NAMS Stock Forecast: NewAmsterdam Pharma Co. NV Price Predictions for 2026-2027

Last close, 4 Nov 2026
$21
+5.08% on the day

The 16 Wall Street analysts covering NewAmsterdam Pharma Co. NV hold a median 12-month price target of $51 — +144.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 4 Nov 2026 — in the upper half.

Market cap
$2.3B
Ticker Nerd rank
57/ 100
Median analyst target
$51
Analysts covering
16
Revenue$3.7M−80.7% y/y
Operating income−$64.9M
Net income−$64.1M
Free cash flow−$39.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.8%
1M
−9.9%
YTD
−40.4%
1Y
−42.8%
From 52W high
−49.6%
From 52W low
+7.1%
$20
$41
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NAMS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NewAmsterdam Pharma Co. NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
57/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
86
Volatility
74
Value
74
Accruals
60
Quality
57
Momentum
35
Growth
34
Issuance
34
Size
33

Revisions (86): Analysts have, on balance, been raising their forecasts.

Issuance (34): The company has been issuing shares or taking on financing, diluting existing holders.

Size (33): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NAMS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NAMS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26NAMSHigh $60Median $51Low $38

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
15 Buy1 Hold0 Sell
Low $38Median $51High $60

The green dot is the last close — the median target sits +144.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
5 Oct 2026RBC CapitalMaintainsOutperform$50 → $42
8 Sept 2026HC Wainwright & Co.ReiteratesBuy—
8 Sept 2026HC Wainwright & Co.ReiteratesBuy$52
6 Aug 2026RBC CapitalMaintainsOutperform$51 → $50
6 Aug 2026RBC CapitalMaintainsOutperform—
30 June 2026RBC CapitalMaintainsOutperform$47 → $51
30 June 2026RBC CapitalMaintainsOutperform—
19 Feb 2026GuggenheimMaintainsBuy—
18 Feb 2026NeedhamMaintainsBuy—
21 Jan 2026RBC CapitalMaintainsOutperform—
16 Dec 2025StifelMaintainsBuy—
2 Dec 2025Goldman SachsMaintainsNeutral—
6 Nov 2025RBC CapitalMaintainsOutperform—
5 Nov 2025NeedhamMaintainsBuy—
20 Oct 2025HC Wainwright & Co.AssumesBuy$52
17 Oct 2025CitigroupMaintainsBuy—
25 Aug 2025Wells FargoInitiatesOverweight—
7 Aug 2025RBC CapitalMaintainsOutperform—
17 July 2025Goldman SachsInitiatesNeutral—
17 June 2025CitigroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

NAMS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NAMS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, NewAmsterdam Pharma Co. NV returned −42.8% against +14.8% for the S&P 500, dividends included.

NAMS vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26NAMSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NAMS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
4
Fundamentals

NewAmsterdam Pharma Co. NV (NAMS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.2×

Cheaper than 94% of US stocks

Price / sales
334.1×

Cheaper than 2% of US stocks

Price / book
3.7×

Cheaper than 25% of US stocks

EV / EBITDA
−7.1×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
−80.7%

Higher than 3% of US stocks

Earnings growth (YoY)
−80.7%

Higher than 5% of US stocks

Gross margin
—
Operating margin
−1752.6%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−36.8%

Higher than 25% of US stocks

Return on assets
−20.1%

Higher than 19% of US stocks

Dividend yield
3.3%

Higher than 88% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

NewAmsterdam Pharma Co. NV (NAMS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • NewAmsterdam Pharma Co. NV has a market value of $2.3B and an enterprise value of $1.7B.

  • Revenue in the twelve months to 30 June 2026: $7.1M. The latest quarter shrank 80.7% year on year.

  • Net income over the same four quarters: −$259.5M, a −3644.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$143.7M.

  • Shares outstanding: 117.7M.

  • Trailing P/E: −11.2×; forward P/E: −13.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 3.32%, paying out 0% of earnings.

  • NewAmsterdam Pharma Co. NV employs 100 people — $71K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

NAMS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NAMSNewAmsterdam Pharma Co. NV$2.3B57
PHVSPharvaris NV$2.4B42
ADMAADMA Biologics, Inc.$2.3B60
PVLAPalvella Therapeutics, Inc.$2.3B36
MBXMBX Biosciences, Inc.$2.5B44
RXRXRecursion Pharmaceuticals, Inc.$2.3B61
VCELVericel Corp.$2.3B94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NewAmsterdam Pharma Co. NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NAMS news & analysis

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Beats Revenue Estimates

Zacks Investment Research · 4 Nov 2026positive

NewAmsterdam Pharma reported a quarterly loss of $0.14 per share, compared with the Zacks consensus estimate of a $0.50 loss. The headline also states that revenue beat estimates, though no revenue figures were provided.

Why it matters — NAMS watchers may note the reported per-share loss was smaller than the consensus estimate and that the company beat revenue estimates.

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November

GlobeNewsWire · 3 Nov 2026neutral

NewAmsterdam Pharma announced that management will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 10, 2026.

Why it matters — The conference appearance is an opportunity for investors to hear from company management about NewAmsterdam Pharma.

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 2 Oct 2026neutral

NewAmsterdam Pharma's Compensation Committee approved the grant of inducement share options covering 71,800 ordinary shares to seven non-executive new hires, awarded as an inducement material to their acceptance of employment under the company's 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — NAMS watchers would note that the company is bringing on new staff and tying their recruitment to share-based incentives under Nasdaq rules, which may signal ongoing hiring and talent expansion.

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer's Disease

GlobeNewsWire · 29 Sept 2026neutral

NewAmsterdam Pharma announced it has dosed the first participant in its Phase 2b SPINOZA trial evaluating obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer's disease who do not yet show noticeable memory or functional symptoms. The study will assess changes in blood-based Alzheimer's biomarkers, including p-tau 217, along with cognitive and functional measures.

Why it matters — This marks a new clinical indication for obicetrapib beyond cardiovascular disease, which NAMS watchers would follow as it expands the company's pipeline into early-stage Alzheimer's disease.

FAQ

Frequently asked questions about NAMS stock

What is the NAMS stock price forecast for 2026-2027?

The 16 Wall Street analysts covering NewAmsterdam Pharma Co. NV have a median 12-month price target of $51, with estimates ranging from $38 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NAMS stock a buy right now?

Of the 16 analysts covering NewAmsterdam Pharma Co. NV, 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NewAmsterdam Pharma Co. NV 57 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NAMS?

As at 4 Nov 2026, NewAmsterdam Pharma Co. NV ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (86 of 100).

Will NAMS stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +144.3% from the last close, and Ticker Nerd's factor model ranks NewAmsterdam Pharma Co. NV 57 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NAMS stock forecast for 2030?

No analyst covering NewAmsterdam Pharma Co. NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NAMS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $60 over the next 12 months.

How has NAMS stock performed over the past year?

NewAmsterdam Pharma Co. NV returned -42.8% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NewAmsterdam Pharma Co. NV do?

NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company focused on developing oral therapies for cardiometabolic diseases, especially patients whose current lipid-lowering treatments are not adequately effective or well tolerated.

What is the latest news on NAMS?

The most recent item we track (Zacks Investment Research, 4 Nov 2026): "NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Beats Revenue Estimates". NewAmsterdam Pharma reported a quarterly loss of $0.14 per share, compared with the Zacks consensus estimate of a $0.50 loss. The headline also states that revenue beat estimates, though no revenue figures were provided.

Company

About NewAmsterdam Pharma Co. NV.

NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company focused on developing oral therapies for cardiometabolic diseases, especially patients whose current lipid-lowering treatments are not adequately effective or well tolerated. The company’s lead program centers on obicetrapib, a low-dose oral CETP inhibitor being studied as a monotherapy and in combination with ezetimibe to help lower LDL cholesterol in cardiovascular settings. NewAmsterdam Pharma also works on broader applications for cardiometabolic care, reflecting its emphasis on non-statin medicine and patient-friendly treatment options. Headquartered in Naarden, the Netherlands, NewAmsterdam Pharma Company N.V. serves the biotechnology and pharmaceuticals market by advancing drug candidates aimed at addressing unmet needs in long-term cardiovascular risk management.

CEO Dr. Michael Harvey Davidson FACC, Facp., M.D. · 100 employees · Netherlands · https://www.newamsterdampharma.com